Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Research output: Book/ReportCommissioned report

Original languageEnglish
Commissioning bodyNational Institute for Health and Care Excellence
Publication statusPublished - 4 Mar 2021

Cite this